Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06632600 · ClinicalTrials.gov registry record · Phase 2
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
A Phase 2 study of Chagas Disease, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 18
- Study locations
NCT06632600 is a Phase 2 study of Chagas Disease that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 130 participants. The trial reports 18 study locations across 11 states.
The verdict
NCT06632600, a Phase 2 study of Chagas Disease, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 18
- Study locations
Study Summary
This study is to investigate the ability of LXE408 to clear or reduce the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without severe organ dysfunction.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LXE408
- DRUG Benznidazole
Study Locations (18)
Other
- Novartis Investigative Site - Corrientes
- Novartis Investigative Site - Córdoba
- Novartis Investigative Site - Formosa
- Novartis Investigative Site - Bogotá
- Novartis Investigative Site - Bogotá
- Novartis Investigative Site - Floridablanca
- Novartis Investigative Site - San Gil
Buenos Aires
- Novartis Investigative Site - CABA
- Novartis Investigative Site - CABA
California
- Olive View UCLA Educ and Res Ins - Sylmar
Florida
- University of Florida Shands - Gainesville
Massachusetts
- Boston Medical Center - Boston
Texas
- Baylor College of Medicine - Houston
Minas Gerais
- Novartis Investigative Site - Montes Claros
Rio de Janeiro
- Novartis Investigative Site - Rio de Janeiro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2030-09-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06632600
The ClinicalTrials.gov registry entry for NCT06632600 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chagas Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06632600 reports 18 study locations spanning 11 distinct geographic areas - top geographies include Other, Buenos Aires, California.
Frequently Asked Questions
What is clinical trial NCT06632600 about?
NCT06632600 is a clinical study titled "A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.". This study is to investigate the ability of LXE408 to clear or reduce the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without severe organ dysfunction.
What is the current status of trial NCT06632600?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2025-04-28. Estimated completion is 2030-09-21.
What conditions does trial NCT06632600 study?
This clinical trial studies the following conditions: Chagas Disease.
What interventions are being tested in trial NCT06632600?
The interventions under investigation include: Placebo (DRUG), LXE408 (DRUG), Benznidazole (DRUG).
Who is sponsoring clinical trial NCT06632600?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06632600 being conducted?
This trial has 18 study locations across California, Florida, Massachusetts, Texas, Buenos Aires. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chagas Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.